Sigma’s attempt to snatch control of API appears to have been thwarted, with rival bidder Wesfarmers exercising its call option over 19.3% API shares to put it in a dominant blocking position.Read More
Sigma Healthcare has come over the top of Wesfarmers and made a non-binding cash and share offer for rival chemist Australian Pharmaceutical Industries that seems to have grabbed the lead in the battle.Read More
Outdoor retailer Kathmandu and pharmacy group Sigma have both given early hints of the damage the lockdowns since June have done to some retailers, with both reporting weak sales and earnings.Read More
Sigma Healthcare shares took the loss of CEO Mark Hooper surprisingly well yesterday, given the surprise nature of the announcement and the lack of any real explanation.Read More
Last week it was AGL revealing the shock departure of its CEO. Today, Sigma Healthcare made the surprise announcement that CEO Mark Hooper will go after more than 10 years in the role.Read More
Sigma Healthcare has reported a $59 million net profit after tax for the year to January, much better than the $12.3 million loss for 2019-20.Read More
Shares in pharmaceutical wholesaler Sigma Healthcare hit their highest level in more than two and a half years yesterday after the company revealed a solid upgrade to expected earnings.Read More
Another solid update from e-tailer Kogan, Qantas investors have given the airline the biggest thumbs down imaginable in rejecting help the company boost its liquidity while Sigma Healthcare has sold and leased back two of its Distribution Centres (DC’s) for $172 million, half the number of centres in the original deal.Read More
UBS estimates a combined earnings benefit of $8m for Sigma Healthcare from 2021 on the basis of the pharmacy wholesale funding in the seventh Community Pharmacy Agreement.Read More
Three results including two from yesterday – from Nufarm and Sigma Healthcare – confirm that the figures are historical and useless for assessing the company’s outlook for the rest of the year and into 2021 in the wake of the impact of COVID-19.Read More
Sigma Healthcare has downgraded FY20 operating earnings (EBITDA) guidance to $46-47m. This comes as of result of reclaiming the FMCG portion of the Chemist Warehouse contract and given the necessity to reinvest in the business.Read More
Underlying earnings (EBIT) were ahead of guidance in FY19, although UBS notes earnings quality was affected by restructuring costs and weak cash conversion. The company has indicated FY20 underlying operating earnings (EBITDA) will be $55-60m.Read More
Shares in Sigma Healthcare resisted early selling pressure yesterday after the pharmaceutical and health group revealed slightly better than expected results for the 2018-19 financial year.Read More
Sigma Pharmaceuticals has rejected the offer from Australian Pharmaceutical Industries ((API)). The company has reiterated its view that there is potential on a stand-alone basis with identified cost savings of over -$100m.Read More
Sigma Healthcare (SIG) shares slumped 15% at one stage yesterday after rejected a half-hearted takeover offer from rival Australian Pharmaceutical Industries (API).Read More
Shares in Sigma Healthcare slumped 11% after yesterday after the drugs supply group revealed the cost of cleaning up the company’s structure after losing the lucrative Chemist Warehouse supply contract.Read More
Sigma Healthcare shares plunged 44% at one stage yesterday after it confirmed that it would not be continuing as a key supplier to the giant Chemist Warehouse chain in a new deal from July 1, 2019.Read More
Lower sales amid a softer consumer environment plus the loss of a key customer saw Sigma Healthcare suffer fall in full-year underlying revenue and earnings for 2017-18 financial year.Read More
Shares in pharmaceuticals and health products supplier Sigma Healthcare jumped more than 4% yesterday after the company met lowered guidance, revealed a new acquisition and reaffirmed it was on track for higher earnings in the next year.Read More
Shares in pharmaceuticals group Sigma Healthcare plunged almost 30% at one stage yesterday after the company revealed it had started legal action against My Chemist (MC), which owns the Chemist Warehouse (CW) brand.Read More
Drugs distributor and pharmacy services firm Sigma Pharmaceuticals is one Australian company that should be poised to build on an already robust export performance into China following that country’s dramatic change of heart on e-commerce rules a week ago.Read More
Surprise on the upside and you will be rewarded, even in a dodgy market like yesterday and its nasty near 1% plus sell off.Read More
Sigma Pharmaceuticals lifted final dividend 50%, from 2 cents to 3 cents a share, despite warning of slowing earnings growth over the next two years.Read More
SigmaPharmaceuticals is paying an interim dividend of 2 cents a share (none previously) after lifting underlying half year profit as it becomes less reliant on revenue from the Pharmaceutical Benefits Scheme (PBS).Read More
Despite its optimism, drugs maker and distributor Sigma Pharmaceuticals would probably wonder why its 2007 annual result was given a bit of a roughing up by the market yesterday.
The shares fell 8c to $2.55 despite signs the merger with Arrow Pharmaceuticals was paying off with a solid pipeline of new generic drugs, higher sales and margins and of course better profits.
Perhaps investors were taken aback by the ‘static’ in the result from the new accounting rules or perhaps the result had been well anticipated by last week’s short run up in the shares above $2.60 so some easy profits were taken.
The market overall was up by around half a per cent and the healthcare sector on the whole was better with small price rises for rivals Symbion (+1c to $3.71) and API (+6c to $2.12).
The outlook commentary seemed confident enough with SIP expecting underlying profit growth of 10 to 15 per cent for the 2007-08 financial year.
Sigma reported a full year net profit for 2006/07 of $101.8 million, which was down 2.9 per cent on the prior year but before tax earnings rose 34.1 per cent to $134.6 million, showing the impact of the Arrow merger which happened in December 2005.
According to some brokers the underlying result looked a bit short of pre-release estimates with some forecasting earnings up around the $120 million mark.
Sigma said the main reason for the decrease in net profit after tax (NPAT) was the impact of a significant item in the 2006 result.
As a result of Sigma’s merger with Arrow Pharmaceuticals, Sigma was required to restate tax values for various Sigma assets.